Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharma has upside potential with a high-end fair value estimate of $481 per share. The company's cash-rich balance sheet and strong free cash flow generation reduce overall equity risk compared to other biotechs. The approval of Vertex's gene-editing therapy for sickle cell disease opens the door for more gene-editing therapies in the future, in our view.

Vertex Pharmaceuticals Is One Of Our Favorite Biotech Ideas

Vertex Pharmaceuticals Incorporated (VRTX) J.P. Morgan 42nd Annual Healthcare Conference

Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report?

Puma Biotechnology

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Puma Biotech (PBYI) and Vertex Pharmaceuticals (VRTX). But which of these two stocks offers value investors a better bang for their buck right now?

PBYI vs. VRTX: Which Stock Is the Better Value Option?

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company's scheduled webcast from the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 11:15 a.m. ET/8:15 a.m. PT. “2023 was marked by continued strong performance in the cystic fibrosis business and acceleration of our development stage pipeline, propelling the company into 2024 with tremendo.

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Brookfield Infrastructure Partners L.P.

Brookfield Infrastructure

Netflix

Starbucks

IBM is an underappreciated tech stock. Brookfield Infrastructure and Starbucks pay reliable dividends.

5 Top Stocks to Buy in January

Amylyx Pharmaceuticals

Vertex Pharmaceuticals' cystic fibrosis franchise is successful, but it's also running out of room to grow. Expected results from a trial with an experimental pain reliever called VX-548 could push Vertex Pharmaceuticals' stock price much higher in 2024.

2 Biotech Stocks With Huge Catalysts in 2024

Disney

Tilray Brands

Tesla

Uber

Gen Z stocks aren't typical, because the generation has a unique relationship with the stock market. Just like Gen Z is the first to grow up fully immersed in digitization and the Internet culture, active market investing and trading is just another fact of life for a sizeable subset.

Gen Z's Top Picks for 2024: 7 Trending Stocks Among Young Investors

CRISPR Therapeutics

Intuitive Surgical

Betting on healthcare's future via healthcare stocks is one of the safest long-term bets you can make. Though changes and advances happen rapidly, healthcare is one industry that is here to stay.

3 Healthcare Stocks to Make You the Millionaire Next Door: 2024 Edition

Brookfield Renewable Partners

MercadoLibre

Brookfield Renewable expects to deliver 12% to 15% average total returns per year. MercadoLibre is poised for continued growth in Latin America.

January Has Been 1 of the Worst Months for the S&P 500 Over the Last 20 Years. Here Are 3 Stocks to Buy Anyway.

AbbVie

Health Care Select Sector SPDR Fund

As we break into the new year, investors are on the hunt for the best biotech stocks to buy. Indeed, 2024 could witness groundbreaking advancements in technology and science.

3 Biotech Stocks Set for Breakthroughs in 2024

Axsome Therapeutics

Novo Nordisk

Axsome Therapeutics could be in store for a breakout year in 2024. Novo Nordisk remains cheap, considering its growth prospects.

Prediction: These 3 Stocks Will Soar in 2024

Microsoft

Brookfield Renewable has a clear growth runway. Microsoft is well positioned to profit from the AI boom.

Want $1 Million in Retirement? Invest $300,000 in These 3 Stocks and Wait a Decade.

Airbnb

Healthcare and travel spending remain at all-time highs. Vertex just hit another huge business milestone.

2 Exceptional Growth Stocks Up 42% and 66% to Buy Right Now

Amazon

Amazon has plenty of room to grow in e-commerce and cloud services. MercadoLibre is the top player in the fast-growing Latin American e-commerce and fintech markets.

3 Monster Stocks to Buy Without Any Hesitation

D.R. Horton

Alphabet

Alphabet could extend its momentum with a strong economy and the launch of a powerful new AI model. D.R. Horton stands to benefit from potential interest rate cuts in 2024.

3 Top Stocks to Buy Hand Over Fist Before the End of 2023

Apple

Abbott Labs

Johnson & Johnson

Coca-Cola

Your year-end bonus looks great now. But it may look even better in a few years if you invest it in some top-quality stocks.

5 Top Stocks to Buy With Your End-of-the-Year Bonus

Amgen

AstraZeneca

BioMarin Pharmaceutical

Bristol-Myers

Blueprint Medicines

Karuna Therapeutics Inc

Pfizer

Roche Holding AG

SPDR S&P Biotech ETF

A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.

Biotech stocks set for a rebound in 2024, analysts say

Gilead Sciences

Investors in search of high-risk, high-reward investments can often find them among the top biotech stocks to buy. Identifying worthwhile opportunities can be easier said than done when investing in biotech.

3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone'

Vertex's cystic fibrosis treatments have generated blockbuster revenue over time -- and growth continues. The company now is wrapping up a pivotal program meant to address one of the most common health problems.

Is Vertex Pharmaceuticals Sitting on a Gold Mine?

Recursion Pharmaceuticals

Zymeworks Inc

On the heels of the devastating COVID-19 pandemic, investor enthusiasm for biotech stocks waned as the Federal Reserve embarked on its aggressive rate-hiking campaign to bring down the red-hot inflation that ensued.

Biotech breakthroughs: Stocks that soared from medical innovations

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 11:15 a.m. ET/8:15 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on t.

Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8

Vertex (VRTX) and CRISPR get a positive CHMP opinion, recommending the conditional approval of Casgevy for the treatment of SCD and TDT.

Vertex (VRTX), CRISPR Get Positive CHMP Opinion for Gene-Therapy

GlaxoSmithKline

Eli Lilly

Regeneron Pharmaceuticals

Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.

5 Big Drug Stocks That May Continue to Outperform in 2024

These stocks are set to benefit from artificial intelligence and gene editing, two game-changing technologies. Companies investing in these technologies today could see their earnings take off over time.

News for Vertex Pharmaceuticals Stock (VRTX)